. References 1. Vangipuram R , Tyring SK . Epidemiology of Kaposi sarcoma: review and description of the nonepidemic variant . Int J Dermatol 2019 ; 58 : 538 – 542 . 29888407 2. Grayson W , Pantanowitz L . Histological
Search Results
Anaplastic Classic Kaposi Sarcoma: PD-L1 Expression and Response to Immunotherapy: A Case Report and Review of the Literature
Ivan Lolli, Anna Maria Valentini, Angela Dalia Ricci, and Raffaele Armentano
Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature
Medhavi Gupta, Christopher Sherrow, Maghan E. Krone, Edik M. Blais, Michael J. Pishvaian, Emanuel F. Petricoin III, Lynn M. Matrisian, Patricia DeArbeloa, Gary Gregory, Alyson Brown, Olivia Zalewski, Gillian Prinzing, Charles Roche, Kazunori Kanehira, Sarbajit Mukherjee, Renuka Iyer, and Christos Fountzilas
reviewed by the Perthera molecular tumor board, the one who most closely resembled our current patient experienced a partial response to an NTRK inhibitor (entrectinib) and, at the time of study publication, had continued on therapy for >1 year. 9
Guidelines of the National Comprehensive Cancer Network on the Use of Myeloid Growth Factors with Cancer Chemotherapy: A Review of the Evidence
Gary H. Lyman
The prophylactic use of myeloid growth factors reduces the risk of chemotherapy-induced neutropenia and its complications, including febrile neutropenia and infection-related mortality. Perhaps most importantly, the prophylactic use of colony-stimulating factors (CSFs) has been shown to reduce the need for chemotherapy dose reductions and delays that may limit chemotherapy dose intensity, thereby increasing the potential for prolonged disease-free and overall survival in the curative setting. National surveys have shown that the majority of patients with potentially curable breast cancer or non-Hodgkin's lymphoma (NHL) do not receive prophylactic CSF support. In this issue, the National Comprehensive Cancer Network presents guidelines for the use of myeloid growth factors in patients with cancer. These guidelines recommend a balanced clinical evaluation of the potential benefits and harms associated with chemotherapy to define the treatment intention, followed by a careful assessment of the individual patient's risk for febrile neutropenia and its complications. The decision to use prophylactic CSFs is then based on the patient's risk and potential benefit from such treatment. The routine prophylactic use of CSFs in patients receiving systemic chemotherapy is recommended in patients at high risk (>20%) of developing febrile neutropenia or related complications that may compromise treatment. Where compelling clinical indications are absent, the potential for CSF prophylaxis to reduce or offset costs by preventing hospitalization for FN should be considered. The clinical, economic, and quality of life data in support of these recommendations are reviewed, and important areas of ongoing research are highlighted.
CLO21-022: Efficacy and Safety Outcomes With Therapies for Stage I-III Merkel Cell Carcinoma (MCC): A Systematic Literature Review
David Miller, Roberto Palencia, Ting Yu, Amrita Sandhu, Sarah Webb, Tom Blaikie, and Murtuza Bharmal
literature review was conducted to understand how patients with early-stage MCC are treated and assess efficacy and safety of current therapies. METHODS: Embase and PubMed were used to identify publications from January 2014 to October 2019, capturing
Gleason Scoring at a Comprehensive Cancer Center: What’s The Difference?
Natasha C. Townsend, Karen Ruth, Tahseen Al-Saleem, Eric M. Horwitz, Mark Sobczak, Robert G. Uzzo, Rosalia Viterbo, and Mark K. Buyyounouski
have been made regarding the need for a second confirmatory pathology review (SPR) before beginning treatment. Furthermore, no reported series have examined the impact of an SPR for men receiving external-beam radiotherapy. Of the 2 series that examine
QIM23-131: A Retrospective Review of Myelodysplastic Syndrome Management (MDS) at Watson Clinic LLP: From Diagnosis to Primary Course of Treatment
Shane Burke, Galina Vugman, Noreen McGowan, and Michelle Sharrett
peripheral blood and bone marrow evaluation to measure extent of disease and risk of progression. Methods: A retrospective review of 69 patients diagnosed with MDS between Jan 1, 2015–Dec 31, 2019 at a community based cancer center was performed to
HSR22-149: Adverse Events Among Cancer Patients Treated With a Combination of Nivolumab and Ipilimumab as Compared to Nivolumab Monotherapy: A Systematic Review and Meta-Analysis
Shweta Kamat, Jay Patel, Britny Brown, and Ami Vyas
Objectives : Combination immune checkpoint inhibitors (ICIs) have demonstrated long-term clinical benefit but are associated with serious treatment-related adverse events (TRAEs). We performed a systematic review and meta-analysis to examine the
HSR21-067: What Patient-Reported Outcomes Are Being Used in Non-small Cell Lung Cancer? A Targeted Literature Review of Randomized Clinical Trials and Regulatory Labeling
Kajal Patel, Soham Shukla, Jennifer Hanlon, Kelly Bell, Laurie Eliason, and Cosmina Hogea
ePROVIDE, an online resource of clinical outcomes assessment, for inclusion of PRO claims in FDA or EMA drug labeling, and clinicaltrials.gov for PRO inclusion as an endpoint in NSCLC randomized clinical trials. Prescribing information was reviewed from
Therapeutic Advances in Relapsed or Refractory Multiple Myeloma
Kenneth C. Anderson
disease. Durie BGM. Concise Review of the Disease and Treatment Options; Multiple Myeloma, Cancer of the Bone Marrow. 2011/2012 ed. International Myeloma Foundation; North Hollywood, CA. Available at http://myeloma.org/pdfs/CR2011-Eng_b1.pdf . Accessed
HSR23-110: Immune Checkpoint Inhibitor (ICI) Treatment After Progression on Anti–PD-1 Therapy in Advanced Melanoma: A Systematic Review of the Literature
Daniel Olson, Brian Gastman, Alicia Rowell, Madan Jagasia, Parameswaran Hari, Wen Shi, Kendall Stevinson, and Katy K. Tsai
inconsistent reporting of response criteria and methods for mPFS and mOS. Conclusion: ICI retreatment is used in clinical practice; however, our systematic literature review found no randomized trials supporting the use of ICI after anti–PD-1. Limited
